Usefulness of 18F-FDG-PET/CT in the diagnosis and prediction of recurrence of pancreatic neuroendocrine neoplasms
- 1 July 2020
- journal article
- research article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 27 (7), 414-420
- https://doi.org/10.1002/jhbp.734
Abstract
Background Although F-18-FDG-PET/CT is a widely used diagnostic tool for several malignancies, its efficacy in diagnosing pancreatic neuroendocrine tumors is reported to be controversial because of the short-term follow-up. Methods We retrospectively compared demographics and pathological features between F-18-FDG-positive and -negative diseases. Additionally, we evaluated whether the avidity of F-18-FDG-PET/CT affected earlier recurrence after curative treatment of non-functioning tumors. The median duration of observation was 65.6 months. Results Seventy-two patients were enrolled. F-18-FDG-positive diseases were pathologically advanced and significantly associated with metastatic behavior. In a multivariate analysis, metastatic behavior and WHO tumor grade was independently associated with F-18-FDG accumulation. Only 25% of functional tumors (4/16) and 8% of insulinomas (1/12) were F-18-FDG-positive. In a Kaplan-Meier analysis in patients with non-functioning tumors (n = 56), F-18-FDG-positivity was significantly correlated with poorer recurrence-free survival (RFS) but had no correlation with overall survival. In univariate analysis of factors associated with shorter RFS, male gender, prevalence of nodal metastasis, WHO tumor grade >= G2, or F-18-FDG-positive disease were significantly higher in patients with shorter RFS, whereas only F-18-FDG-positivity was associated with shorter RFS in multivariate analyses. Conclusions The avidity of F-18-FDG-PET/CT was associated with metastatic behavior of pancreatic neuroendocrine tumors and recurrence after treatment of non-functioning tumors.This publication has 26 references indexed in Scilit:
- Prognostic Value of Volumetric Parameters of Pretreatment 18F-FDG PET/CT in Esophageal CancerClinical Nuclear Medicine, 2018
- Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1Journal of Clinical Endocrinology & Metabolism, 2017
- Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumorsNuclear Medicine Communications, 2016
- Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- PET/CT imaging in cancer: Current applications and future directionsCancer, 2014
- Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysisThe Esophagus, 2014
- When should FDG‐PET be used in the modern management of lymphoma?British Journal of Haematology, 2013
- 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancerWorld Journal of Gastroenterology, 2011
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008